National Cancer Institute
National Cancer Institute U.S. National Institutes of Health

Thoracic Malignancy Steering Committee

The NCI Thoracic Malignancy Steering Committee (TMSC) was established in 2008. Members of the TMSC include all Cooperative Group lung/thoracic disease committee chairs, Specialized Programs of Research Excellence (SPORE), Cancer Center and R01/P01 translational science investigators along with community oncologists, biostatisticians, patient advocates and NCI staff.

Mission Statement

The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase III trials and large phase II studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma. Esophageal cancer trials are reviewed by the Gastrointestinal Cancer Steering Committee.

Roster of Thoracic Malignancy Steering Committee (TMSC) members
A. William Blackstock, M.D., David H. Harpole Jr., M.D., and Mark A. Socinski, M.D., Co-chairs

Clinical Trial Planning Meetings (CTPMs): Goal of Clinical Trial Planning Meetings, and List of CTPM Executive Summaries and Publications

Active Protocols

CCCT Contact: Susan Rossi, Ph.D.